Updated:
Shinsei Aoyama Partners
新生キャピタルパートナーズ株式会社 is a life science investment firm whose mission is to support the practical application of research from universities, research institutions,...
Shinsei Aoyama Partners
新生キャピタルパートナーズ株式会社 is a life science investment firm whose mission is to support the practical application of research from universities, research institutions, and pharmaceutical companies by providing financial backing, helping deliver innovative medicines. The firm operates the New Life Science No. 1 fund and invests in drug-discovery ventures across company-creation, seed, early, middle, and later stages, drawing on experience in finance and pharmaceutical development.
General information
Firm type
Private Equity Firm
Year founded
2019
Location
Region
Asia
Country
Japan
City
Tokyo
Corporate office
Tokyo, Japan
Principals
中村 学（代表取締役）
山川 善之（取締役）
薦田 貴久（取締役）
佐久間 大輔（取締役）
小島 冬樹（監査役）
Sector focus
Frequently asked questions
What is Shinsei Aoyama Partners' core investment thesis?
The firm targets succession-driven buyouts of Japanese small-to-mid-cap enterprises. It acquires companies from retiring founders who have no internal successor, then works to professionalize management, upgrade financial controls, and build durable operational infrastructure for long-term stewardship. The thesis is a direct bet on Japan's demographic structure — an aging business-owner class with limited exit options outside of selling to a trusted institutional buyer.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: